Navigation Links
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Date:8/19/2007

VANCOUVER, Aug. 14 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. (TSX: DDD; OTCBB: DRUG; BBSE: DRP) today announced the financial results for the second quarter ended June 30, 2007.

Highlights of the Second Quarter, 2007

- Sales increased 48% to $20.55 million from $13.89 million for the

same period of 2006, and increased 19% as compared to the first

quarter 2007;

- Gross profit and gross margin increased to $3.98 million and 19.36%

from $2.39 million and 17.24% for the same period of 2006;

- Operating income increased 5.6 times to $1.17 million from

$0.18 million in the same period of 2006;

- Net income was $0.45 million, compared to a net loss of $0.32 million

for the same period of 2006. Net income for the second quarter of

2007 was net of a non-cash stock based compensation of $1.02 million.

Strong Sales Growth in the Low Season

Dragon experienced significant revenue growth in the second quarter of 2007 which was normally regarded as the low season during the year. Net sales increased 48% to $20.55 million from $13.89 million for the same period of 2006 and increased 19% sequentially as compared to the first quarter of 2007. The Company experienced revenue growth for all three divisions with 37%, 134% and 44% year-over-year growth rate for the Chemical, Pharma and Biotech divisions respectively.

The revenue growth was mostly driven by the increase in both the sale volume and the price of 7ACA product. As the prices for Penicillin intermediates tripled during the past 12 months, more customers have turned to other alternatives such as cephalosporin drugs, which have led to the increase in both the sale volume and price for 7ACA product. During the quarter, 146 tons of 7ACA were sold, which were 107% of the 137 tons of production output.

The Company has also increased its export sales of Clavulanic Acid by 26% compared with th
'/>"/>

SOURCE Dragon Pharmaceutical Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Chinese pharma-biotech dragon rears its head
2. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
3. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
4. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
5. Deltanoid Pharmaceuticals begins phase II osteoporosis study
6. Doing the pharmaceutical tango
7. Want to squeeze U.S. pharmaceutical companies? Be careful what you ask for
8. The Coming of Biotech Generic Pharmaceuticals
9. Knowledge Management: The Key to Success for Life Sciences and Pharmaceutical Companies
10. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
11. Sonic Foundry reports GAAP loss as Q2 revenues rise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... This is a professional and in-depth ... The report provides basic biocides information, including its ... well as industry overview. This research covers the ... well as Global industry analysis covering macroeconomic environment ... Chinese biocides industry covers information on ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
(Date:10/31/2014)... , Oct. 31, 2014  Atlanta-based Intellimedix could ... accompanying the onset of Ebola by suggesting a ... at Georgia Tech,s Center for Computational Systems Biology ... to find alternative uses for existing drugs through ... to aid the bout against Ebola. ...
(Date:10/30/2014)... 30, 2014  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that ... on Thursday, November 6, 2014. Following the announcement, ... conference call and webcast at 4:30pm ET to ... business update. The live webcast can ...
Breaking Biology Technology:Biocides Market for International & Chinese Regional Development Analysis Now Available at DeepResearchReports.com 2Biocides Market for International & Chinese Regional Development Analysis Now Available at DeepResearchReports.com 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Atlanta-Based Intellimedix May Help Solve Ebola With Computer Algorithms 2Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2
... , , , , ... CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a ... the Second and final closing of a private placement financing with ... $5 million. , , As previously reported, ...
... CINCINNATI, Sept. 18 LCA-Vision Inc. (Nasdaq: LCAV ... the Lasik Plus (R) brand, announces that Steven C. Straus ... the company,s board of directors effective September 25, 2009 to ... Management of daily operations will be the responsibility of Chief ...
... 18 Omeros Corporation today announced the launch of its ... stock. Omeros is a clinical-stage biopharmaceutical company committed to ... of the central nervous system. , , ... $10.00 to $12.00 per share. Omeros has applied to ...
Cached Biology Technology:Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million 2Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million 3LCA-Vision Announces CEO Resignation 2Omeros Commences Initial Public Offering of Common Stock 2Omeros Commences Initial Public Offering of Common Stock 3
(Date:10/29/2014)... hair as a consequence of chemotherapy will benefit from ... cooling technology that prevents hair loss. , The research ... global scalp cooling manufacturing company, Paxman Coolers, of Fenay ... the University of Huddersfield. , The research will be ... background in the pharmacology of cancer treatment, which he ...
(Date:10/29/2014)... for the Society of Interventional Radiology,s (SIR) ... the one place where interventional radiologists, diagnostic ... professionals can come together to find the ... presented, discussed and tested. , "Connecting ... medicine, SIR 2015 will feature essential updates ...
(Date:10/29/2014)... industrial products are in the environment – and hundreds ... scientists have yet to determine whether they cause health ... that by estimating which substances people are exposed to ... ACS journal Environmental Science & Technology . , ... to human health of any given substance depend primarily ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... University, the team mapped the presence of foxes in ... their likely distribution as a blueprint for fox eradication, ... of Canberra professor in wildlife genetics and leader of ... northern and eastern Tasmania and the model developed by ...
... CA Researchers from the Carnegie Institution are rolling out ... AToMS, for the first time at the American Geophysical ... and its scientific observations are uncovering a previously invisible ... is helping researchers look at the world in a ...
... MA and SAN FRANCISCO, CADecember 4, 2012 The ALS ... today announced the formation of a research collaboration to ... the preclinical drug development process. "We are ... ALS therapeutic development," said Steve Perrin, PhD, CEO and ...
Cached Biology News:Fox invasion threatens wave of extinction, UC research finds 2Carnegie debuts revolutionary biosphere mapping capability at AGU 2Carnegie debuts revolutionary biosphere mapping capability at AGU 3ALS TDI and Gladstone Institutes collaborate to discover potential ALS treatments 2
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
... 3 x 3 nmol (individual) with ... 3 siRNAs specifically targeted to your target gene ... reagent guarantees you get more than 75% knockdown ... conditions (100 nM siRNA for transfection and confirmation ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... IDS 25-Hydroxy Vitamin D kit is ... determination of 25-hydroxyvitamin D (25-OH D) ... serum or plasma. Our patented DIRECT ... solvent precipitation and centrifugation and therefore ...
Biology Products: